BiotechTube
AilseBio

AilseBio

London, United Kingdom· Est.
ailsebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

AilseBio is an early-stage biotech leveraging its proprietary TiNA Discovery platform to identify novel, therapy-induced antigens for next-generation immunotherapies. Operating from London and founded in 2021, the company is positioned in the high-potential oncology vaccine and immunotherapy space. As a private, pre-clinical stage company, it is likely in a seed or Series A funding phase, building its foundational science and pipeline. Its success hinges on validating its novel antigen discovery approach and translating it into effective clinical candidates.

Oncology

Technology Platform

Proprietary TiNA Discovery platform designed to identify Therapy Induced Novel Antigens (TiNAs) – a new class of antigens revealed or induced by prior cancer therapy, intended for use in developing novel immunotherapies.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The approach targets a major unmet need in converting non-responders to existing cancer therapies into responders by leveraging therapy-induced antigens.
The platform has broad potential applicability across many solid tumor types in combination with standard-of-care treatments, representing a large market opportunity.
Early validation could attract significant partnership interest from large pharma companies seeking novel immuno-oncology assets.

Risk Factors

The core scientific premise of Therapy Induced Novel Antigens is novel and unproven, carrying high biological risk of failure in pre-clinical or clinical testing.
The company faces intense competition from established players and numerous startups in the cancer vaccine and neoantigen space.
As an early-stage, pre-revenue private company, it is highly dependent on securing future funding in a challenging financial climate.

Competitive Landscape

AilseBio competes in the crowded and rapidly evolving field of cancer antigen discovery and therapeutic vaccines. Direct competitors include companies focused on neoantigen prediction and vaccine development (e.g., BioNTech, Gritstone bio, Neon Therapeutics (acquired)), as well as those exploring alternative antigen sources. Its differentiation hinges on the novelty of its TiNA hypothesis, which, if validated, could carve out a distinct niche within the combination therapy paradigm.

More companies in Immunotherapy / Immuno-Oncology →More companies in United Kingdom →